Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Efruxifermin in Compensated Cirrhosis Due to NASH/MASH
jRCT2031260332Phase 3Recruiting
- Sponsor
- Akero Therapeutics
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis due to nonalcoholic steatohepatitis comparing Efruxifermin 50 mg with Placebo (2 arms). Primary endpoints: Time to first significant clinical event and Histologic fibrosis improvement (96 weeks). Started Sep 2026; status: recruiting.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)cirrhosis due to nonalcoholic steatohepatitis
Beyond the preview
Go deeper on jRCT2031260332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260332.